OpenLobby.EU
Explore

EU Life sciences strategy

Research and innovation

The EU has been very strong in the life sciences and well placed to nurture its economy with knowledge, know-how and innovation but it is now losing ground to its main global competitors. This new multi-disciplinary strategy for European life sciences will aim at boosting Europe competitiveness and prosperity, accelerate the twin transition, create new jobs, and reduce dependencies by a faster development, translation and commercialisation of ideas and innovation in Europe.

Links

Public consultation

ID: 14592

Lobbying Activity

121 responses

Danish Industry calls for faster drug approvals and stronger IP

BUSINESSEUROPE, 11 Apr 2025

The group demands faster regulatory approvals matching US timelines and stronger intellectual property protections. They propose a European Life Science Council to advise on reducing administrative burdens.
Stronger intellectual property rights would protect long-term investments and ensure higher returns.
Health systems and generic manufacturers would lose from maintained high drug prices.

AmCham EU urges holistic strategy to boost life sciences competitiveness

American Chamber of Commerce to the European Union, 17 Apr 2025

They propose a Life Sciences Council and a 50% reduction in red tape. They also demand stronger intellectual property rights and international regulatory convergence.
Harmonized global standards and stronger IP rights would secure market positions and lower compliance costs.
European firms with local production could lose competitive advantages from regional investment incentives.

BDI urges ambitious EU strategy to restore life sciences leadership

Bundesverband der Deutschen Industrie e.V., 11 Apr 2025

BDI requests an EU Life Science Office to coordinate policy and streamline regulatory processes. They also demand stronger intellectual property protections and better access to private venture capital.
Stronger IP rules and reduced regulation would protect their market share from global competitors.
International suppliers of medical components lose out as production moves back to Europe.

DIGITALEUROPE urges digital integration in EU life sciences strategy

DIGITALEUROPE, 17 Apr 2025

The group calls for a holistic approach that prioritizes health data. They advocate for harmonized implementation of data laws and innovation hubs. They also request streamlining reporting requirements to ease the business burden.
Unified rules and streamlined reporting would significantly lower administrative costs for companies.
National regulators lose autonomy as the plan targets diverging local interpretations.

EFPIA urges EU strategy to restore pharmaceutical industry leadership

European Federation of Pharmaceutical Industries and Associations, 17 Apr 2025

EFPIA calls for a dedicated EU Office for Life Sciences to coordinate governance. They demand stronger intellectual property protections and streamlined clinical trial approvals to foster innovation.
Simplified regulations and robust patents would lower compliance costs and increase investment.
Environmental groups lose safety protections if restrictions on hazardous substances are bypassed.

Eurogroup for Animals urges non-animal methods in life sciences

Eurogroup for Animals, 17 Apr 2025

They call for a unified EU strategy to replace animal experiments with technology. This includes dedicated funding and harmonized training for researchers.
This transition would eliminate the ethical burden and animal suffering from testing.
Traditional laboratories face significant challenges adapting to complex new regulatory landscapes.

Consultation response

Finnish Forest Industries Federation (Metsäteollisuus ry), 16 Apr 2025

Unlocking Europes Growth Potential Through the Forest Bioeconomy The Finnish Forest Industries Federation (FFIF) supports the European Life Science Strategy and urges that the versatile forest sector should be recognized as a key pillar within it. Europe, particularly Finland and the other…

Bayer calls for regulatory simplification and a Life Sciences Office

Bayer AG, 16 Apr 2025

Bayer proposes establishing a dedicated EU Life Sciences Office to coordinate policy and ensure legislative coherence. They advocate for a Biotech Act that acts as a simplification catalyst for approvals and strengthens intellectual property protections.
These changes would accelerate market entry for innovations and protect high-risk research investments.
Environmental groups may lose stringent hazard-based protections against chemical and biotechnology risks.

Medicines for Europe urges recognition of off-patent innovation in life sciences strategy

MEDICINES FOR EUROPE, 17 Apr 2025

The organization requests that the EU strategy recognize off-patent innovation, reduce regulatory complexity, support competitive market dynamics, and create investment incentives for generic and biosimilar manufacturers. They emphasize expanding the definition of innovation to include manufacturing processes supporting green and digital transitions.
This would unlock state aid and funding for their manufacturing investments and reduce compliance costs.
Innovative pharma companies lose if competition and market entry are prioritized over IP protection.

Confindustria demands EU strategy to lead global Life Sciences

Confederazione Generale dell'Industria Italiana, 14 Apr 2025

Confindustria requests a strategy prioritizing health alongside green and digital transitions. They call for stronger patent protections and a plan to bring manufacturing home.
This would protect Italy's industrial dominance and reduce dependence on foreign suppliers.
Public health systems lose out on lower costs if pharmaceutical reforms are reversed.

MedTech Europe Demands Structural Reform of EU Medical Regulations

MedTech Europe, 17 Apr 2025

The association demands a structural reform of the medical device regulatory system by 2026. They request simpler rules across digital and environmental policies to reduce the cumulative regulatory burden. Finally, they seek strategic funding to modernize European healthcare infrastructure and research.
Streamlined regulations would lower compliance costs and speed up the launch of innovations.
Environmental standards could be weakened by efforts to simplify chemical and packaging laws.

CropLife Europe urges faster approvals for agricultural biotech innovation

CropLife Europe, 16 Apr 2025

CropLife Europe requests faster market access through "provisional authorisations" and a "future-proof definition" of biopesticides. They also advocate for "simplification proposals" for biotechnology, including "eliminating the renewal requirement" for proven imports. Finally, they seek to "unlock the potential" of digital tools in farming.
Faster approvals would reduce compliance costs and speed up product commercialization.
Animal welfare groups may lose protections if "mandatory" toxicity studies are reduced.

Consultation response

The Danish Chamber of Commerce, 14 Apr 2025

Dansk Erhverv takker for muligheden for at bidrage med erhvervslivets perspektiver i forbindelse med den kommende europæiske life sciences strategi. Life Science-sektoren spiller en afgørende rolle for europæisk økonomi og er et enormt aktiv som eksporterhverv for Europa og Danmark (og stod i 2023…

Novo Nordisk urges stronger patent protection and regulatory simplification

Novo Nordisk A/S, 16 Apr 2025

They propose 12 years of market protection for medicines. They want to remove rules that allow others to use their patents. The company requests a single-approval model to simplify clinical trials.
Stronger intellectual property protections would help the company secure its high-risk investments.
Generic drug manufacturers would be delayed from launching cheaper versions of medicines.

EuropaBio urges streamlined EU rules to boost biotech competitiveness

EuropaBio, 16 Apr 2025

EuropaBio calls for a streamlined and predictable legislative environment for all biotech innovators. They urge the EU to accelerate product deployment through favorable market conditions. They also request a dedicated EU Biotech Office to improve policy coordination.
Regulatory simplification and new financial mechanisms would unlock investment for biotech companies.
Fossil-based sectors may lose market share due to targets favoring renewable products.

Invest Europe urges EU to fix life sciences funding bottleneck

Invest Europe, 16 Apr 2025

The organization calls for restructuring the financial ecosystem to support early-stage venture capital. They request harmonized market access and a revised SME definition to unlock investment.
Proposed reforms would lower regulatory barriers and increase capital flow to investment funds.
Public grant providers might lose relevance as the industry shifts toward tax-based incentives.

Sanofi urges EU to double biopharma funding for competitiveness

SANOFI, 17 Apr 2025

Sanofi proposes a coordinated EU strategy including competitiveness checks and doubling biopharma research funding. They also request stronger intellectual property protections and streamlined rules for using artificial intelligence.
These measures would provide greater investment certainty and lower costs for pharmaceutical innovation.
Public health budgets could face higher costs from extended intellectual property protections.

German biotech industry demands unified EU life sciences strategy

Verband der Chemischen Industrie e.V., 17 Apr 2025

The association calls for a unified framework that simplifies regulation. They suggest streamlining permitting processes and harmonizing standards across member states.
Streamlined regulations would lower compliance costs and help companies scale up innovations faster.
Fossil-based industries could lose market share to biotech products favored by new incentives.

AstraZeneca calls for stronger IP to revive EU competitiveness

AstraZeneca PLC, 17 Apr 2025

AstraZeneca demands a "sector omnibus package" to reduce "regulatory duplication" and financial burdens. They argue "innovation relies on robust IP protection" and oppose reducing regulatory data protections. The company seeks to "streamline and accelerate trials" by amending current clinical regulations.
Stronger IP and fewer regulations would protect profits and lower operational compliance costs.
Generic drug makers and environmental groups lose if patent shields expand and pollution rules ease.

Pharma giant MSD urges stronger IP and regulatory coordination

Merck Sharp Dohme Europe Belgium SRL, 17 Apr 2025

MSD recommends establishing an EU Office of Life Sciences to coordinate healthcare and industrial policies. They also advocate for stronger intellectual property rights and the streamlining of multi-country clinical trial applications.
Stronger intellectual property protections would help MSD attract investment and maintain its market exclusivity.
Environmental interests could be compromised by efforts to simplify chemical and ESG regulatory requirements.

European Cancer Organisation urges EU action on medical workforce shortages

European Cancer Organisation, 17 Apr 2025

The organisation calls for a plan to address critical healthcare workforce shortages. They propose union-wide staffing standards and reducing administrative burdens on clinicians. They also advocate for clinical trials to include more diverse groups.
Better staffing levels would allow cancer professionals more time to lead innovation.
Minority groups and rural regions lose out when clinical research is concentrated.

Philips urges EU to simplify medical device regulations and trade

Koninklijke Philips, 17 Apr 2025

Philips calls for a European Life Science Council and the inclusion of large medical device manufacturers. They demand a reduction in regulatory complexity and the removal of transatlantic trade tariffs.
Streamlining regulations and removing tariffs would significantly reduce Philips’ operational costs and market entry delays.
Budget-focused manufacturers would lose their competitive edge as tenders move away from the lowest price.

GSK urges EU to simplify regulations for life sciences innovation

GSK, 16 Apr 2025

GSK advocates for regulatory harmonisation and a new Office for Life Sciences. They request stronger intellectual property standards and research AI exemptions.
These changes would protect proprietary data while reducing regulatory delays and costs.
Environmental groups may see lower safety standards if chemical and environmental regulations are reduced.

EURORDIS urges EU to prioritize rare diseases in life sciences

EUROPEAN ORGANISATION FOR RARE DISEASES, 17 Apr 2025

The organization calls for prioritizing rare diseases by streamlining regulations and increasing research funding. They request that patient organizations be funded as equal partners throughout the research chain.
This would secure sustainable funding and higher political priority for rare disease patient groups.
Drug manufacturers may face reduced profit margins from collective EU pricing and procurement strategies.

Pfizer urges EU life sciences investment to reverse innovation decline

Pfizer Inc., 16 Apr 2025

Pfizer requests stronger intellectual property protections, streamlined regulatory frameworks, and development of biohubs connecting universities and companies. They emphasize positioning healthcare as strategic investment rather than cost, and promoting sustainable procurement without discriminatory 'made in Europe' provisions.
This would attract pharmaceutical R&D investment back to Europe and reduce regulatory compliance burdens.
European manufacturers lose if 'made in Europe' provisions are excluded from public procurement.

Consultation response

DSW (Deutsche Stiftung Weltbevoelkerung), 17 Apr 2025

DSW would urge that the new Strategy build on the strategic priorities of the 2002 Life Sciences and Biotechnology - a Strategy for Europe; balancing the drive for EU competitiveness while unlocking life sciences and biotechnologys potential to deliver solutions to global societal needs. This is…

Merck urges smart regulation to boost EU life sciences

Merck, 16 Apr 2025

Merck calls for life sciences to be recognized as strategic. They seek predictable rules and exemptions to avoid double regulation.
Simplified rules would lower the rising costs associated with chemical evaluations.
Health and environmental groups may face risks from relaxed chemical standards.

EUCOPE urges predictable incentives to boost European life sciences

European Confederation of Pharmaceutical Entrepreneurs, 17 Apr 2025

The confederation calls for maintaining strong and predictable incentives and intellectual property rights. They request streamlined regulatory processes and clinical trials to reduce administrative burdens for developers. Additionally, they propose a specific category for mid-sized companies to address unique barriers.
Smaller firms would benefit from lower administrative costs and easier research commercialisation.

AESGP Urges Regulatory Reform to Boost EU Self-Care Competitiveness

Association of the European Self-Care Industry, 17 Apr 2025

AESGP wants longer data protection for medicines switched to non-prescription status. They request simplified regulatory procedures and a dedicated framework for live biotherapeutic products. The industry seeks a predictable and transparent regulatory environment for medical devices.
These changes would ensure rapid market access and lower costs for consumer healthcare.
European healthcare systems lose billions if limited product access forces more doctor visits.

Novo Nordisk Foundation Urges EU to Prioritize Life Sciences Innovation

Novo Nordisk Foundation, 27 Mar 2025

The foundation recommends standardized guidelines for university intellectual property and increased funding for early-stage projects. They also propose large-scale funds for late-stage investment to keep startups in Europe.
The foundation would see its research projects reach the market faster with less bureaucratic friction.
Regulatory safety advocates lose if the EU adopts a less cautious, innovation-first regulatory model.

Novonesis urges EU to accelerate biosolutions through regulatory reform

Novonesis A/S, 15 Apr 2025

The company wants the EU to speed up approvals for nature-based industrial products and update rules to support a green economy. They suggest shifting away from rules designed for chemicals toward a system based on actual product risks.
Faster approval processes would allow the company to compete globally and reduce significant registration delays.
Traditional fossil-based fertilizer producers face market share loss to more sustainable bio-based alternatives.

Humane World for Animals Urges Non-Animal Life Science Strategy

Humane World for Animals Europe, 17 Apr 2025

The group wants the EU to prioritize non-animal testing methods across research and regulation. They recommend dedicated funding and a clear roadmap to replace animal models with advanced technologies.
Adopting human-relevant models would decrease drug development costs and reduce research failure rates.
Facilities relying on animal models face financial losses as demand for traditional testing declines.

Boehringer Ingelheim urges EU to restore pharmaceutical innovation leadership

Boehringer Ingelheim, 15 Apr 2025

The company calls for an EU Life Sciences Coordinator and a simplification package to reduce regulatory complexity. They also seek strengthened intellectual property rights and more harmonized, faster clinical trial approvals.
Predictable market conditions and regulatory simplification would lower costs and attract more investment.
Environmental protections could be weakened to avoid restricting chemicals used in medicine production.

AnimalhealthEurope urges EU vaccination strategy and regulatory simplification

AnimalhealthEurope, 16 Apr 2025

They urge a coordinated EU response through a specific strategy on vaccination. They advocate for simplifying reporting requirements and improving digital product databases.
Reducing administrative complexity would help the industry focus on its core business.

Ecolab urges streamlined EU biotech and manufacturing rules

ECOLAB, 17 Apr 2025

Ecolab requests the EU modernize manufacturing rules and adopt a clear Biotech Act. They want standard technology definitions to simplify regulatory approvals globally.
Harmonized standards would lower administrative costs and simplify trade for their purification products.

VTT Urges Faster Biotech Approvals and More Infrastructure Funding

VTT Technical Research Centre of Finland Ltd, 16 Apr 2025

VTT requests long-term funding for biotechnology and biomanufacturing to diversify food and health sectors. They urge the EU to accelerate slow regulatory approvals for novel foods and plant protection products. They also call for increased investment in infrastructure to scale up bio-based innovations.
This would increase demand for VTT's specialized research services and pilot facility usage.
Global competitors would lose their market advantage if the EU streamlines its regulatory processes.

Bristol Myers Squibb urges stronger IP and innovation rewards

Bristol-Myers Squibb Company, 17 Apr 2025

BMS calls for stronger intellectual property rights and an ecosystem that rewards innovative products. They argue for increasing healthcare budgets to allow for faster deployment of new treatments.
Enhanced intellectual property protections would safeguard their investments and ensure faster reimbursement for medicines.
Public health payers face higher costs from increased healthcare budgets and delayed generic competition.

CSC Urges Public Data Infrastructure for EU Life Sciences

CSC – IT CENTER FOR SCIENCE LTD., 15 Apr 2025

CSC recommends building shared European data infrastructures linked to supercomputers and AI factories to support research. They call for simplifying regulations and reassessing GDPR data minimisation to facilitate data-intensive innovation. Finally, they advocate for public ownership of infrastructures and sustained funding in the next budget.
Public data centers would benefit from guaranteed funding and a central role in European research.
Privacy advocates could see protections weakened if data minimisation requirements are reassessed for AI development.

European Brain Council Urges Strategy Centered on Brain Health

European Brain Council, 17 Apr 2025

The Council calls for brain research to be recognized as a key economic driver and integrated across all EU policy areas. They advocate for cutting administrative red tape and securing stable, long-term funding streams to support innovation.
Predictable funding and streamlined rules would reduce research disruptions and accelerate the commercialization of neurological treatments.
Animal rights advocates may see their influence diminished as the council defends animal research as essential for scientific progress.

Consultation response

Coalition for Epidemic Preparedness Innovations, 14 Apr 2025

Pandemic preparedness is crucial in an interconnected world. Emerging infectious diseases lead to loss of life, productivity, economic damage, social and political upheaval. Fragmented research hinders international collaboration, a coordinated and well-resourced approach ensure rapid and effective…

Aarhus University seeks broad scope for EU life sciences strategy

Aarhus University, 14 Apr 2025

Aarhus University requests the strategy look beyond pharmaceuticals to include agriculture and biosolutions. The initiative should support technologies that improve agricultural productivity while protecting the environment. Research should focus on replacing fossil-based products with sustainable biological alternatives.
A broader scope increases research opportunities and funding for the university's diverse academic departments.
Traditional fossil fuel industries face increased competition from bio-based chemicals, materials, and fuels.

Dutch greenhouse sector urges more life sciences funding

Glastuinbouw Nederland, 17 Apr 2025

The group requests increased investment in fundamental research and easier funding access for smaller enterprises. They advocate for a triple helix model and improved lifelong learning qualifications.
Streamlined funding and targeted research would help the sector maintain its status as a global leader.
Global competitors lose market share as the EU strengthens its food sovereignty and technological autonomy.

Social insurers urge health focus for life sciences strategy

European Social Insurance Platform AISBL, 17 Apr 2025

The strategy should prioritize patient needs and healthcare sustainability over market dynamics. ESIP demands the maintenance of rigorous regulatory standards and insists that industry incentives be tied to affordability conditions.
These measures would protect the financial stability of national health insurance systems and prevent rising costs for taxpayers.
Pharmaceutical companies may face stricter conditions on incentives and more demanding regulatory hurdles for fast-tracking products.

CSL Behring urges predictable frameworks to boost European biotech innovation

CSL Behring, 17 Apr 2025

CSL Behring calls for predictable frameworks that reward innovation and improve clinical trials. They suggest outcomes-based contracting models and better use of health data. They also recommend targeted revisions to the Clinical Trials Regulation to speed up approvals.
Simpler rules and tax breaks would reduce compliance costs and market barriers.
National health systems lose the power to implement mandatory price-control measures.

Paediatric oncology society urges EU to fund cross-border trials

European Society for Paediatric Oncology, 15 Apr 2025

SIOPE requests reimbursement for cross-border clinical trials to improve patient access. They call for better regulatory support for academic-led research and drug innovation. The group also advocates for harmonised data rules and interoperable digital systems.
This would secure funding and regulatory recognition for non-profit research and development.
Pharmaceutical companies may face stricter requirements if the EU limits regulatory waivers.

German pharmaceutical association BPI urges stronger patents and doubled funding

Bundesverband der Pharmazeutischen Industrie e.V., 17 Apr 2025

BPI calls for a robust and predictable system of incentives and intellectual property rights. They request doubling funding for industry research in the next R&D programme.
Stronger patents and doubled funding would minimize financial risks for pharmaceutical developers.
Non-EU suppliers would lose business as the strategy aims to reduce dependencies.

Edwards Lifesciences seeks faster EU pathways for heart technologies

Edwards Lifesciences, 17 Apr 2025

The company calls for a 120-day priority review process for breakthrough medical devices. They advocate for adapted assessment methods that include real-world evidence and clinical data. They suggest shifting public purchasing to a value-based model to reward innovation.
Faster approval times would allow the company to bring heart technologies to market quicker.
Vulnerable patients suffer when slow regulatory and procurement processes delay access to treatments.

ESMO Urges Placing Cancer at Center of EU Strategy

European Society for Medical Oncology (ESMO), 15 Apr 2025

ESMO requests placing cancer at the center of the life sciences strategy. They want the EU to prioritize therapeutic innovation and medical breakthroughs. The strategy should also support translating research into novel treatments.
This would improve funding for professional education and training in oncology disciplines.

Consultation response

Psychedelic Access and Research European Alliance, 11 Apr 2025

Mental Health Innovation in the EU Life Sciences Strategy Europe stands at a critical juncture in health innovation. Half of us will experience a mental illness in our lifetime. The World Economic Forum warns that poor mental health is a looming global economic emergency. Yet our ability to address…

Consultation response

Aalborg Universitet, 17 Apr 2025

Focus: Biosolutions and yeast and fungi-based technologies. We welcome the EUs initiative and emphasize the need to integrate biosolutions, based on yeast and filamentous fungi into the strategy. These microbial platforms are scalable, resource-efficient, and central to Europes green transition.…

Takeda urges strong IP protections and rare disease action

Takeda Pharmaceuticals International AG, 17 Apr 2025

Takeda recommends preserving predictable incentives and simplifying approval processes for new medicines. They propose maintaining current orphan designation thresholds and adopting a Rare Disease Action Plan. The company also advocates for long-term funding and enhanced health data sharing.
These measures would protect Takeda's high-risk investments and reduce their regulatory burdens.
Generic drug manufacturers may face delayed market entry if current IP protections remain.

Consultation response

Valneva, 12 Apr 2025

VALNEVA SE is a European biotech company developing, manufacturing and commercialising vaccines against infectious diseases with a large unmet medical need. Its affiliate Valneva Austria is a member of BIOTECH AUSTRIA, the association which represents the interests of the growing Austrian…

PHARMIG urges strong IP protection in EU life sciences strategy

PHARMIG - Verband der pharmazeutischen Industrie Österreichs, 17 Apr 2025

The organization calls for a competitive framework for intellectual property and expanded research support measures. They request simplified cross-border clinical trials and targeted funding to reduce dependence on non-European production. Finally, they seek faster regulatory procedures and better secondary use of health data.
These proposals would lower manufacturing expenses and secure long-term profits through IP incentives.
Environmental groups may see ecological standards weakened in favor of industrial competitiveness.

Consultation response

Chiesi Farmaceutici SpA, 17 Apr 2025

The Chiesi Group welcomes the opportunity to contribute to the call for evidence on the upcoming EU Life Sciences strategy. We are a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty…

Roche calls for streamlined rules to revive EU innovation

F. Hoffmann-La Roche Ltd, 15 Apr 2025

Roche demands a streamlined regulatory system with a single body for clinical trials and integrated healthcare solutions. They advocate for stronger intellectual property protections and improved industry access to health data.
Simplified approval processes and robust patent protections would reduce administrative costs and safeguard R&D investments.
National governments would lose regulatory autonomy, while environmental groups may see sustainability standards deprioritized.

Consultation response

The Good Food Institute Europe (Belgium), 4 Apr 2025

GFI Europe welcomes the opportunity to contribute to the European Commission's call for evidence on the strategy for European life sciences. We acknowledge that a strong life sciences sector is essential for the EU to maintain its leadership in industrial biotechnology, particularly in the food…

INRAE urges EU to expand life sciences strategy to agri-food

Institut national de recherche pour l’agriculture, l’alimentation et l’environnement, 17 Apr 2025

INRAE calls for a broad strategy including agricultural and environmental sciences. They request increased research funding and faster regulatory approval for new innovations.
Sustained funding and market access would help them commercialize new agricultural technologies.
Citizens could face health risks if regulatory sandboxes lack robust safety oversight.

Cruelty Free Europe urges non-animal methods for life sciences

Cruelty Free Europe, 16 Apr 2025

Cruelty Free Europe demands that non-animal methodologies lead the new life sciences strategy. They want the EU to prioritise funding for modern technologies while phasing out animal testing. The group advocates for regulatory changes to speed up the adoption of non-animal tests.
Adopting these methods would fulfill the group's mission of ending animal testing in European labs.
Traditional research facilities using animal models would face significant funding cuts and regulatory hurdles.

Consultation response

Plants for the Future European Technology Platform, 11 Apr 2025

Plants for the Future welcomes the initiative to develop A Strategy for European Life Sciences, as they play a crucial role in our society. As a European Technology Platform representing the plant sector and promoting the flow of innovation from basic research to the market, we highlight the…

Regenerative medicine group urges EU to lead in advanced therapies

Alliance for Regenerative Medicine, 17 Apr 2025

ARM calls for aligned industrial and health policies to support advanced therapies. They advocate for streamlining clinical trial rules to speed up patient access.
The sector would benefit from a more predictable market and increased investment.
Global competitors will lose market share if Europe regains its lead.

Novamont Urges EU Strategy to Mandate Bio-based Content Targets

Novamont SpA, 17 Apr 2025

Novamont calls for mandatory bio-based content targets and financial incentives for bioeconomy products. They request dedicated NACE codes and simplified waste valorization to improve circularity. They also advocate for promoting compostable plastics in agriculture and packaging.
Mandatory targets and financial incentives would secure market demand for Novamont’s bio-based products.
Producers of traditional plastics would face market displacement and competitive disadvantages from bio-based alternatives.

Consultation response

EIT Food ivzw, 17 Apr 2025

EIT Food welcomes the upcoming publication of the Life Sciences Strategy and appreciates the Commissions efforts to gather input from stakeholders to feed into its preparation, as well as that of the Bioeconomy Strategy and the future EU Biotechnology Act. A better understanding of the challenges…

Consultation response

Medtronic, 17 Apr 2025

Medtronic believes that the EU life sciences strategy represents a pivotal moment for European healthcare and healthcare delivery. Providing the timely opportunity and policy to intelligently help transform Europes healthcare and health delivery models to be a force for health, growth and jobs. The…

Consultation response

Oulun yliopisto, 16 Apr 2025

Innovation in Europe is hampered by overregulation, and EU is lagging behind other continents. This can be seen both in the difficulty of processing health data and in the regulation of device development and testing. The Life Sciences sector in Europe is of vital economic and societal importance.…

BioMed Alliance calls for reform of European life science sector

Biomedical Alliance in Europe, 17 Apr 2025

They call for a reform of the life science sector through strengthening investment in research. They propose creating a multi-stakeholder structure to provide leadership and coordination for health research.
These measures would streamline research processes and formalize the time professionals spend on innovation.
Competing sectors like defense and artificial intelligence would lose potential budget allocations to health research.

Consultation response

Karolinska Institutet, 17 Apr 2025

Please find attached the University Alliance Stockholm Trio's comments and input to A strategy for European life sciences. (Stockholm Trio is a university alliance between Karolinska Institutet, KTH Royal Institute of Technology, and Stockholm University).

Consultation response

Cellular Agriculture Europe, 16 Apr 2025

Cellular Agriculture Europe welcomes the opportunity to submit a contribution to the call for evidence on the European Commissions EU Life Sciences Strategy. The attached document outlines our views and proposed measures to support the European life sciences ecosystem, and its potential…

Consultation response

International Flavors & Fragrances, 17 Apr 2025

IFF is a global leader with 30% footprint in Europe, providing innovative B2B solutions for food, beverage, health, biosciences and scent sectors. Our ingredient products deliver sustainable and competitive solutions for our customers - without compromising on performance. Our offering enables many…

Consultation response

Associazione delle Imprese del farmaco, 17 Apr 2025

Farmindustria, in linea con EFPIA e con lurgenza manifestata dalle Aziende, accoglie con favore liniziativa della Commissione UE per una Strategia UE sulle Life Sciences, quale chiave per rafforzare la competitività di un settore che assicura salute, sviluppo e sicurezza, in una fase decisiva per…

Consultation response

YouthProAktiv, 16 Apr 2025

YouthProAktiv (YPA) work focuses on youth empowerment, education, entrepreneurship, and civic participation, and we strongly advocate for more inclusive innovation systems that engage young people meaningfully in Europes future. We believe the Life Sciences Strategy must address not only…

Consultation response

Centre de coopération internationale en recherche agronomique pour le développement, 17 Apr 2025

Prevention measures against pandemics are estimated to be 100 times less costly than control measures. Moreover, pandemics and other large scale growing health problems like antimicrobial resistance and cancers, can severely hit the organisation and economy of our societies. In this context, the EU…

Consultation response

Association of Manufacturers and Formulators of Enzyme Products, 17 Apr 2025

AMFEP, the Association of Manufacturers and Formulators of Enzyme Products, representing 90% of the EU enzyme market, welcomes the opportunity to comment on the EU Life Sciences Strategy. Enzymes are proteins produced in nature by all living organisms. They are a crucial element of life sciences…

Consultation response

EU-LIFE, 16 Apr 2025

EU-LIFE alliance input for the European Life Sciences Strategy is provided in the attached file.

Consultation response

European Association of Urology, 15 Apr 2025

The European Association of Urology (EAU) welcomes the opportunity to contribute to the EU Life Science Strategy call for evidence. As a leading authority in urological research and clinical practice, we are committed to advancing healthcare through innovative data initiatives and evidence-based…

Consultation response

Läkemedelsindustriföreningen, 15 Apr 2025

Important Factors for the EU Life Sciences Strategy The life sciences sectorencompassing pharmaceuticals, medical devices, in vitro diagnostics, medical software, and biotechnologyis one of Swedens most strategic industries. With over 52,000 employees, it is a key driver of job creation and…

Consultation response

Stichting Wageningen Research, 17 Apr 2025

Biotechnological advancements are needed in sustainable food production, starting from animal and plant breeding. We emphasize the need for strong R&I in breeding and biotechnology, integrating AI to drive innovation. Europe has the potential to become leader in Life Sciences and innovation. To…

Consultation response

Biogen, 17 Apr 2025

Biogen welcomes the creation of a European Life Sciences Strategy. As a global biotechnology leader with significant presence and investment in Europe, Biogen is committed to advancing first-in-class treatments and therapies across a range of disease areas, including rare diseases. As such, we…

Consultation response

Consejo Superior de Investigaciones Científicas, 17 Apr 2025

With more than 16.000 employees and 121 research institutes, the Spanish National Research Council (CSIC) is the largest public research performing organisation (RPO) in Spain, and holds a prominent role in the European Union (EU) and internationally. Its LIFE global area represents the largest and…

Consultation response

EIT Health, 17 Apr 2025

EIT Health welcomes the European Commission's commitment to reinforce Europes competitiveness through A strategy for European life sciences. A European Life Sciences strategy should address better support for start-ups and SMEs, de-risking mechanisms for private investment, stronger…

Consultation response

Verband Forschender Arzneimittelhersteller e.V., 17 Apr 2025

As the German association representing research-based pharmaceutical companies, vfa (Verband Forschender Arzneimittelhersteller e.V.) strongly advocates for a bold and forward-looking European Life Sciences Strategy. The life sciences sector, which includes the research-based pharmaceutical…

Consultation response

Kungliga Tekniska Hoegskolan, 17 Apr 2025

KTH welcomes and supports the European Commission's initiative to create a European Life Science Strategy, acknowledging its potential to foster innovation and strengthen Europe's global leadership in health, biotechnology, food and sustainable solutions. 1. The investment landscape: The…

Consultation response

Breakthrough T1D, 16 Apr 2025

As the largest global funder of type 1 diabetes (T1D) research, Breakthrough T1D is uniquely positioned to offer insights into how Europe can strengthen its life sciences ecosystem, particularly in translating cutting-edge science into life-changing therapies. Currently, Breakthrough T1D supports…

Consultation response

Nuclear Medicine Europe, 15 Apr 2025

Each day, over 100,000 patients worldwide benefit from nuclear medicinea vital area of healthcare that uses medical isotopes for early diagnosis and targeted treatment, particularly in oncology. As this field evolves rapidly, it promises more personalized, precise, and effective care. With demand…

Consultation response

European Society of Radiology, 17 Apr 2025

The European Society of Radiology (ESR) applauds the initiative to create a Strategy for European Life Sciences aiming to advance life sciences-based innovation across Europe by addressing key barriers and to re-install Europes competitiveness and status as global leader. It is important to ensure…

Consultation response

Hollandbio, 16 Apr 2025

Europe worked hard to become a leader in life sciences. But while the rest of the world is taking the next step, we are blocking ourselves. Innovations get stuck in rules and regulations, talent moves elsewhere, and other continents capitalize on European breakthroughs. If we dont act now, Europe…

Consultation response

Deutsche Forschungsgemeinschaft, 11 Apr 2025

The European life sciences sector is facing increasing systemic pressures resulting from excessive regulatory complexity. While robust regulation remains necessary given the sensitivity of topics such as patient data, animal experimentation, and genetic resources, recent developments suggest a…

Consultation response

Netherlands Federation of University Medical Centres, 17 Apr 2025

See the document attached.

Consultation response

Fondazione Telethon ETS, 17 Apr 2025

Fondazione Telethon welcomes the European Commissions initiative to develop an EU Life Science Strategy that can drive scientific excellence, support patient-centred innovation, and strengthen Europes competitiveness. One of the most promising area in life science is the development of Advanced…

Consultation response

European Plant Science Organisation, 17 Apr 2025

European Plant Science Organisations (EPSO) response to the call for evidence for A Strategy for European Life Sciences The European Plant Science Organisation (EPSO) welcomes the initiative to develop A Strategy for European Life Sciences. EPSO is an independent academic organisation that…

Consultation response

The International Aids Vaccine Initiative Inc, 17 Apr 2025

Call for Evidence: A Strategy for European Life Sciences Response from IAVI IAVI welcomes the opportunity to contribute to the development a new Life Sciences Strategy. We believe the EU has a critical role to play in fostering innovation in health and addressing some of the worlds most pressing…

Consultation response

RISE Research Institutes of Sweden AB, 16 Apr 2025

In response to this Call for Evidence A Strategy for European Life Sciences, we at RISE Research Institutes of Sweden ABa state-owned, independent research institute have compiled a position paper outlining what we consider to be essential actions to strengthen Europes life science sector. Our…

Consultation response

European Aquaculture Technology and Innovation Platform, 15 Apr 2025

The European Aquaculture Technology & Innovation Platform (EATiP) thanks the European Commission for the opportunity to provide comment in a Call for Evidence concerning a strategy for European Life Sciences EATiP is a not for profit multi actor platform considering and promoting technology,…

Consultation response

Fachverband der Chemischen Industrie Österreichs, 17 Apr 2025

Der Fachverband der Chemischen Industrie (FCIO) begrüßt die Initiative der Europäischen Kommission zur Entwicklung einer umfassenden Strategie für die Biowissenschaften und deren industrielle Umsetzung. Diese Strategie stellt eine herausragende Möglichkeit dar, Europas industrielle Basis zu stärken…

Consultation response

Verband der Diagnostica-Industrie, 17 Apr 2025

Ja zu einer europäischen Life Science Strategie Forschung und Entwicklung sichert den Wirtschaftsstandort Europa im internationalen Wettbewerb. Gerade in Zeiten einer Rezession ist die Finanzierung von Forschung und Entwicklung elementar, um mit Inventionen und Innovationen Schwung in die…

Consultation response

European Association of Nuclear Medicine, 17 Apr 2025

The European Association of Nuclear Medicine (EANM) welcomes the opportunity to provide feedback on the European Life Sciences Strategy. Please find the EANM feedback attached.

Consultation response

European Research Infrastructure for Translational Medicine, 16 Apr 2025

EATRIS ERIC, the European Research Infrastructure for Translational Medicine, welcomes the European Life Sciences Strategy, which will provide a fillip to EU competitiveness. As recently concluded in the 2024 ERA scoreboard, Europe remains weak in knowledge valorisation relative to its immense…

Consultation response

Biobanking and Biomolecular resources Research Infrastructure-European Research Infrastructure Consortium, 16 Apr 2025

As BBMRI-ERIC, the Biobanking and Biomolecular Resources Research Infrastructure - European Research Infrastructure Consortium, we support the initiative and call for evidence regarding a strategy for European life sciences. We share our detailed response in the attached document.

Consultation response

European Society of Human Reproduction and Embryology, 14 Apr 2025

With regard to key emerging research areas, ESHRE would like to emphasise the importance of reproductive medicine as a core area of life sciences. Please find attached a document presenting several topics from this field on which further research is expected to have a particularly high and…

Consultation response

European Coalition to End Animal Experiments, 14 Apr 2025

The European Coalition to End Animal Experiments (ECEAE) warmly welcomes the EU Life Sciences Strategy and requests that the final draft includes the promotion of alternatives to animal testing as one of the areas to benefit from it. The desire to work towards a Europe where animal testing is no…

Consultation response

OGM dangers, 2 Apr 2025

Madame, Monsieur, J'ai lu avec attention votre document préparatoire. Je vous propose de le relire et je pense que vous verrez apparaître le dit et le non dit. Le dit est clair (même si je ne le partage pas). Le non dit est plus intéressant car c'est dans ce non dit que se logeront les anicroches…

Consultation response

Miller International Knowledge, 23 Mar 2025

In response to the European Commissions Call for Evidence Title of Initiative: A Strategy for European Life Sciences Date: 23rd March 2025 Organisation: Miller International Knowledge (MIK) Type of organisation: Independent legal and ethical advisory organisation Website:…

Consultation response

Chemelot Circular Hub, 17 Apr 2025

The combined strengths of BRIGHTLANDS CHEMELOT CAMPUS and BRIGHTLANDS MAASTRICHT HEALTH CAMPUS form one of Europes most dynamic life sciences ecosystems. With industry leaders like MEDTRONIC, LONZA, and BASIC PHARMA, in synergy with academic and clinical research partners, we strongly welcome the…

Consultation response

European Federation of Allergy and Airways Diseases Patients' Associations, 17 Apr 2025

The European Federation of Allergy and Airways Diseases Patients Associations (EFA) is the voice of 200 million people living with allergy, asthma, and chronic obstructive pulmonary disease (COPD) in Europe. EFA strongly supports integrating a health-in-all-policies approach in all decisions and…

Consultation response

Euro-BioImaging ERIC, 17 Apr 2025

Euro-BioImaging ERIC welcomes the ECs initiative to develop a strategy for European Life Sciences. As a European Research Infrastructure Consortium (ERIC), we provide open access to cutting-edge biological and biomedical imaging technologies, essential for advancing research, innovation, and…

Consultation response

The International Life Sciences Institute, Europe, 17 Apr 2025

Since providing science-based guidance to food sector on food safety, nutrition & health and sustainability is the core mission of ILSI Europe, we appreciates the opportunity to provide input to the EU Life Science strategy. Please find the document attached.

Consultation response

EURAMET e.V., 17 Apr 2025

Metrology, the science of measurement, is key for the quality infrastructure in health and is instrumental to accelerate the innovation process for new European medical products for high-quality and efficient healthcare. While metrology and metrological traceability of results is a required…

Consultation response

Nordic Wellbeing Academy, 17 Apr 2025

To meet the demands of 21st-century public health and innovation, the future European Union life science strategy should elevate a new paradigmone rooted not only in scientific excellence and economic growth but in collaborative governance, data-informed learning systems, co-created health…

Consultation response

Association of Clinical Research Organizations, 16 Apr 2025

The Association of Clinical Research Organizations (ACRO) is pleased to provide the attached document. Please see attached PDF. Thank you. Respectfully submitted, Karen Noonan Senior Vice President of Global Regulatory Policy Association of Clinical Research Organizations (ACRO)

Consultation response

Stichting Lygature, 16 Apr 2025

On behalf of Foundation Lygature, please find attached our response to call for evidence on A strategy for European life sciences. Although there are many factors important for a high performing ecosystem, weve focused our input on the Call for Evidence by the European Commission on those topics in…

Consultation response

Asociácia inovatívneho farmaceutického priemyslu/Association of Innovative Pharmaceutical Industry, 16 Apr 2025

AIFP, a member of EFPIA, welcomes the European Commissions initiative to develop a robust EU Life Sciences Strategy to strengthen Europes competitiveness and close the innovation gap with global peers. The strategy must address challenges across the full value chain, deepen public-private…

Consultation response

European Biosafety Association, 16 Apr 2025

The European Biosafety Association (EBSA) welcomes the Call for Evidence on the EU life sciences strategy. Detailed feedback can be found in the attached position paper. For ease of reference, the executive summary is copied here below. EBSA remains fully available to engage further on any of the…

Consultation response

Sveriges Kommuner och Regioner, 16 Apr 2025

Sveriges Kommuner och Regioner (SKR) anser att: -en multidisciplinär och sektorsöverskridande EU-strategi för life science behöver fungera som ett komplement till befintliga nationella strategier; -strategin behöver utformas från ett bottom up-perspektiv som erkänner den roll som lokala och…

Consultation response

Università Vita-Salute San Raffaele, 16 Apr 2025

Università Vita-Salute San Raffaele (UniSR) welcomes the European Commissions commitment to fostering Europes ability to deliver scientific and technological advancements to the benefit of its citizens. The forthcoming EU Life Sciences Strategy should build on this commitment and further expand the…

Consultation response

Sociedad Española de Hematología y Oncología Pediátricas, 15 Apr 2025

SIOPE, the European Society for Paediatric Oncology, represents healthcare professionals committed to delivering care and research in childhood cancer across Europe. Despite significant increases in survival rateslargely driven by academic, cross-border collaborationchildhood cancer remains the…

Consultation response

UNDO software, 15 Apr 2025

Input from the EU B-trust project on the life sciences strategy. More info on the project: https://btrustproject.eu/ Input on the life sciences strategy: The B-Trust project explores why biotechnological solutions in the agri-food and bio-based sectors sometimes face limited acceptance. Through…

Consultation response

Swedish Medtech, 15 Apr 2025

Important Factors for the EU Life Sciences Strategy The life sciences sectorencompassing pharmaceuticals, medical devices, in vitro diagnostics, medical software, and biotechnologyis one of Swedens most strategic industries. With over 52,000 employees, it is a key driver of job creation and…

Consultation response

Diagnostics For Animals (formely European Manufacturers of Veterinary Diagnostics), 14 Apr 2025

Executive summary 1. The animal health and food safety diagnostic sector are strategic contributors to the EU Animal Health, Animal Welfare and Food policies and are committed to reducing harm to people, animals and our environment through diagnostic products and services. The Veterinary and Food…

Consultation response

Lægemiddelindustriforeningen, 11 Apr 2025

A EU Life Science strategy should be focused on health innovation and not be so broad that its focus and impact declines. It should focus on pharmaceuticals, medical technology, digital health solutions and biotech within pharma. In 2024, Denmark launched just such a focused life science strategy…

Consultation response

Consortium of European Taxonomic Facilities, 11 Apr 2025

The proposed Strategy for European Life Sciences presents an opportunity to position the EU as a global leader in innovation. However, the call for evidence document currently underrepresents the foundational role of ecosystems, biodiversity, as well as taxonomy as fundamental science pillar for…

Consultation response

Genewatch UK, 10 Apr 2025

Past investments in genomic science and technology, led by vested interests, have led to poor economic decisions and a failure to tackle deep-seated socio-economic problems. Misplaced investments and technological and scientific failures have resulted in significant opportunity costs. Decisions…

Consultation response

Rare Diseases Ireland, 9 Apr 2025

The EU life sciences strategy must give hope to the millions of people living with rare diseases in Europe and around the world. We have reached a tipping point as regards new innovative medicines, devices and technologies, including big data and AI. This strategy must ensure that member states…